Is methylene blue better than CoQ10?

For mitochondrial and cognitive endpoints, its subratings say yes: 8.0 against 7.0 on mitochondrial and 6.8 against 4.5 on cognition, and it wins eleven of seventeen shared use cases. For overall risk-adjusted value, no: CoQ10 scores 7.1 against 6.1 because methylene blue's downside total is 1.804 against 0.679, driven by drug interactions.

Why does CoQ10 score higher if methylene blue wins most use cases?

Because the overall score weights downside, and methylene blue's is nearly three times CoQ10's. It inhibits MAO-A, which excludes anyone on an SSRI, SNRI, MAOI, tramadol, dextromethorphan or linezolid, and it is contraindicated in G6PD deficiency. CoQ10's only meaningful interaction is warfarin. A compound most adults cannot safely take scores lower even when it works better.

Can I take CoQ10 and methylene blue together?

Pharmacologically yes, and it is rarely necessary. They occupy different compartments of the same electron transport chain, CoQ10 between Complexes I and III and methylene blue cycling at cytochrome c oxidase, so there is no redundancy and no listed interaction between them. Every methylene blue screening requirement still applies unchanged.

Which one works faster?

Methylene blue, by about two weeks. Its first noticeable change lands at roughly two hours and its speed subscore is 4.5 against CoQ10's 2.8. CoQ10 takes about two weeks to first signal. Both reach full effect at 12 weeks, so the early difference is how soon you feel something, not how long either takes to finish working.

Do I need to test for G6PD before taking methylene blue?

Yes, and it is the first thing on the list. G6PD deficiency is a contraindication on the PROVAYBLUE label because methylene blue can cause hemolysis in deficient people. It is a routine blood test. If you are in a higher-prevalence population and untested, get the test before the vial, not after a reaction.

Should I take CoQ10 with my statin?

It is reasonable to try, with realistic expectations. Banach 2015 confirmed statins lower plasma CoQ10 by 0.44 micromol/L, and Qu 2018 pooled 12 RCTs finding less muscle pain, weakness, cramp and tiredness. Taylor 2015 crossed 41 people with confirmed statin myopathy over 600 mg/day and found nothing. Give it twelve weeks at 100 to 200 mg/day and judge honestly.

Is aquarium-grade methylene blue the same molecule?

The molecule may be, and what comes with it is not. Its report requires USP or pharmaceutical grade and states plainly that aquarium-grade and industrial dye are never acceptable. The approved product is a prescription injection for methemoglobinemia. Oral microdosing is off-label use of a drug, and it is not a place to economize on the source.

Does CoQ10 lower blood pressure?

Probably not meaningfully. Rosenfeldt 2007 pooled 12 trials and reported large systolic reductions, but that analysis was dominated by uncontrolled open-label data. The 2016 Cochrane review restricted itself to 2 controlled RCTs in 50 people and found systolic and diastolic changes that were both nonsignificant, concluding no clinically significant effect.

Head-to-Head Comparison

CoQ10 vs Methylene Blue: Which Is Better for Energy?

Should I take CoQ10 or methylene blue?

Reviewed 09/08/2026

CoQ10 scores 7.1 and methylene blue 6.1, yet methylene blue wins eleven of the seventeen shared use cases. The overall gap is risk, not effect. Methylene blue inhibits MAO-A, so it carries a serotonin-syndrome interaction list CoQ10 does not have. CoQ10 is the one with hard mortality data behind it.

Methylene blue wins mitochondrial 8.0 to 7.0, cognition 6.8 to 4.5, energy 6.8 to 6.0, sleep 5.5 to 2.0 and mood 5.5 to 2.5, despite scoring a point lower overall.
That overall gap is downside. Methylene blue's downside total is 1.804 against CoQ10's 0.679, almost all of it interaction risk.
Only CoQ10 has hard outcome data. Q-SYMBIO (Mortensen 2014) randomized 420 heart failure patients and cut major cardiac events from 26% to 15% while halving cardiovascular mortality.
Methylene blue is a potent reversible MAO-A inhibitor (Ramsay 2007), so SSRIs, SNRIs, MAOIs, tramadol, dextromethorphan and linezolid are all hard exclusions. The FDA issued a safety communication about this in 2011.
G6PD deficiency rules out methylene blue outright because of hemolysis risk. Test before, not after.
Speed differs completely: methylene blue gives a first change in about two hours on a 4-week window, CoQ10 in about two weeks on a 12-week window.
Costs are nearly identical, $15 to $40 a month for CoQ10 and $13 to $40 for microdosed methylene blue. Both are estimates. Aquarium-grade dye is never acceptable.

At a Glance

Option B

Methylene Blue

6.1 / 10 Worth trying

Upside

Efficacy 4.0
Breadth 3.5
Evidence 4.2
Speed 4.5
Durability 3.0
Bioindividuality 2.4

Downside

Safety Risk 4.0
Side Effects 2.2
Cost 1.8
Effort 1.3
Opportunity Cost 1.4
Dependency 1.2
Reversibility 1.5

Best at:

Mitochondrial 8.0
Cognition Focus 6.8
Energy 6.8
Memory 6.5

Redox-cycling phenothiazine dye and FDA-approved antidote. BioHarmony 6.1, worth trying.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
Mitochondrial	Methylene Blue	Methylene blue 8.0 against CoQ10's 7.0, its highest subrating on the page. Mechanistically, methylene blue acts as an alternative electron carrier that bypasses damaged complexes entirely, cycling at cytochrome c oxidase. CoQ10 replaces a cofactor the chain already uses between Complexes I and III. Bypassing broken machinery beats topping up working machinery.
Cognition Focus	Methylene Blue	Methylene blue 6.8 against CoQ10's 4.5, the widest gap in the matrix. The human data is real but small: Rodriguez 2016 gave 26 people a single 280 mg oral dose and increased task-related fMRI response and short-term memory retrieval accuracy. That is one acute dose in 26 people, not a nootropic protocol, and CoQ10 has nothing here.
Energy	Methylene Blue	Methylene blue 6.8 against 6.0, and the difference you would notice is timing rather than magnitude. Methylene blue's first noticeable effect lands at about two hours and its speed subscore is 4.5 against CoQ10's 2.8. CoQ10's energy case builds over weeks and shows up as exercise capacity in Lei 2017 rather than as a felt lift.
Acute Pain	Coenzyme Q10 (CoQ10 / Ubiquinol)	CoQ10 5.5 against methylene blue's 4.0, the only shared row CoQ10 wins, and it is a migraine result. Sandor 2005 randomized 42 people to 300 mg/day and reported a 50%-responder rate for attack frequency of 47.6% against 14.4% on placebo. Methylene blue's pain data is surgical local infiltration after hemorrhoidectomy, a different route and a different question.
Neuroprotection	Methylene Blue	Methylene blue 6.5 against CoQ10's 4.5, with a caveat worth more than the score. Its neuroprotective case rests on cerebral oxygen consumption support and the tau-aggregation hypothesis, and the large test of that hypothesis was equivocal: Gauthier 2016 ran a phase 3 trial of the LMTX methylthioninium derivative with mixed interpretation. Not a consumer nootropic proof.
Sleep Quality	Methylene Blue	Methylene blue 5.5 against CoQ10's 2.0. CoQ10 has no sleep mechanism at all, so this is a win by default rather than by evidence. Read it against methylene blue's own contraindication list, which names anxiety disorders prone to sympathetic overdrive. A compound that inhibits MAO-A is not an obvious sleep aid, and neither report holds a sleep trial.
Metabolic Health	Methylene Blue	Methylene blue 6.5 against 4.5, with blood sugar running 5.5 against 4.0 on the same logic. The mechanism is mitochondrial electron cycling improving substrate handling, and it is inference rather than trial data on either side. Neither report holds a metabolic RCT in healthy people. Treat this row as mechanism-weighted.
Immune Function	Methylene Blue	Methylene blue 5.5 against CoQ10's 2.5. Most of its clinical evidence sits in acute critical care rather than in immune enhancement: Huang 2024 pooled 6 RCTs and 265 participants in distributive shock and found shorter mechanical ventilation, ICU stay and hospital stay with mortality uncertainty. Hospital data, not a supplement claim.
Healthspan	Tie	Call this even, against the subratings. Methylene blue scores 6.5 and CoQ10 4.5, but the only hard outcome data on this page belongs to CoQ10. Q-SYMBIO halved cardiovascular mortality in heart failure and KiSel-10 cut cardiovascular mortality from 12.6% to 5.9%. Healthspan means events avoided, and methylene blue has avoided none in a healthy population.
Longevity	Tie	Both 6.0, an exact tie, and both are mechanism-weighted rather than outcome-weighted. No trial on either compound has tested lifespan. CoQ10's supporting data is cardiovascular mortality in sick populations. Methylene blue's is redox cycling. Neither is a longevity purchase on this evidence.
Antioxidant	Tie	Methylene blue 6.0 against CoQ10's 5.5, inside the noise and worth calling even because they work in different compartments. CoQ10 is the main membrane-phase antioxidant, protecting cell membranes and circulating LDL, and Gao 2012 pooled 5 trials showing improved flow-mediated dilation. Methylene blue cycles in the aqueous phase. Neither substitutes for the other.
Endurance Cardio	Tie	Methylene blue 5.5 against CoQ10's 4.5, and the evidence points the other way. Lei 2017 pooled 14 RCTs and 2,149 people in cardiac failure and found improved exercise capacity alongside a mortality risk ratio of 0.69, with LVEF and NYHA class not significant. Methylene blue has no exercise-capacity trial. Score favors one, human data favors the other.

Cost Comparison

Intervention	Monthly Cost	Notes
CoQ10	$15 to $40	ESTIMATE, priced 2026-09-07, ordinary supplement retail. Generic ubiquinone runs $15 to $40 a month at 200 mg/day, the top of the 100 to 200 mg protocol range. Better-absorbed ubiquinol runs $30 to $60, and the premium is defensible: Langsjoen 2014 crossed 12 subjects over both forms at 200 mg/day and plasma CoQ10 reached 4.3 mcg/mL on ubiquinol against 2.5 on ubiquinone.
Methylene blue	$13 to $40	ESTIMATE, priced 2026-09-08, retail and compounding channel. A pharmaceutical-grade or properly compounded solution runs $40 to $120 per vial and lasts months at microdose levels, so spreading one vial over three months at 0.5 to 5 mg/day gives roughly $13 to $40 a month. The cheap product in this category is aquarium-grade dye, which is not a cheaper version of the same thing.
The difference	Effectively nothing, so cost should not decide this	The two ranges overlap almost completely, $15 to $40 against $13 to $40, so price is not a tiebreaker here the way it is on most of these pages. Decide on interaction risk and on what you are trying to fix.One cost asymmetry does exist. CoQ10 needs no verification beyond picking ubiquinol or an oil-based softgel. Methylene blue's report marks purity verification as required, and the correct product is USP or pharmaceutical grade from a compounding pharmacy, which is where the top of its price range comes from.

When to Switch

Their clocks are the most different of any pair in this set. Methylene blue gives a first noticeable change in about two hours with a 4-week assessment window.

CoQ10 takes about two weeks to first signal and 12 weeks to full effect, on a 12-week window. Both reach full effect at 12 weeks, so the difference is entirely in how early you get a signal, not in how long the compound takes to finish working.

Switch from CoQ10 to methylene blue when the target is cognitive or acute and twelve weeks of CoQ10 produced nothing you could name. CoQ10 scores 4.5 on cognition and 2.0 on sleep, so there was never much there.

Before you do, check three things in this order: a G6PD result, your full medication list against the MAO-A interaction, and whether the product is pharmaceutical grade. Any one of those failing ends the conversation.

Switch the other way, from methylene blue to CoQ10, whenever a cardiac reason enters the picture, whenever you start a statin, or whenever a serotonergic medication does. Banach 2015 showed statins drop plasma CoQ10 by 0.44 micromol per liter, which is the mechanistic basis for co-supplementing, and Q-SYMBIO is the only hard-outcome trial on this page.

Running both is pharmacologically reasonable, since they occupy different compartments of the same chain, and it is rarely necessary. If you do, the interaction screening for methylene blue applies unchanged.